Epratuzumab and Rituximab Have Strong Showing Against Follicular Lymphoma

Biopharmaceutical company Immunomedics announced that the combination of epratuzumab and rituximab as a front-line therapy for patients with newly diagnosed follicular non-Hodgkin's lymphoma (FL) resulted in a very high complete response rate among the small cohort as well as prolonged time to disease progression.

The company had the combination in the Phase II CALGB 50701 study, sponsored by the National Cancer Institute Study Group, Cancer and Leukemia Group B (CALGB). The findings appear online in the journal Cancer.

The overall response rate (ORR) among 59 evaluable patients was 88.2 percent.

Of these:
- 25 patients (42.4 percent) achieved a complete response
- 27 patients (45.8 percent) reported a partial response
- 6 patients (10.2 percent) had stable disease as their best response.

The estimated median progression-free survival is 3.5 years.

At 3 years, 60 percent of patients remain in remission.

Said Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics:

We are very encouraged with these high efficacy results of epratuzumab when combined with rituximab in patients with NHL who are naive to therapy. Further development of this humanized anti-CD22 antibody will be an international Phase III study conducted by the Resistant Disease Committee of the International BFM Study Group to improve the outcome of children and adolescents with acute lymphoblastic leukemia.

Epratuzumab is Immunomedics' proprietary humanized anti-CD22 antibody. It has shown efficacy as a monotherapy in relapsed FL. Although rituximab combined with chemotherapy has improved the survival of previously untreated patients with FL, many patients are unable or unwilling to tolerate chemotherapy.

Therefore CALGB chose to evaluate the combination of epratuzumab and rituximab as front-line therapy.

Source: WSJ

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...